Login / Signup

Conversion to tacrolimus alone compared to full immunosuppression following cardiac transplantation (TACTFUL).

Aaron P PearstonAmanda I IngemiZachary A ShaefferChad M CameronKatharine T BiagiMyra GobbleAmin YehyaDavid A Baran
Published in: Clinical transplantation (2023)
Selected patients who do not tolerate combination immunosuppression can be safely transitioned to tacrolimus monotherapy as a means of controlling adverse events without an increased risk of mortality or rejection.
Keyphrases
  • cardiovascular events
  • left ventricular
  • combination therapy
  • open label
  • risk factors
  • cell therapy
  • cardiovascular disease
  • stem cells
  • heart failure
  • randomized controlled trial
  • coronary artery disease
  • double blind